The first long-acting injectable treatment for HIV infection in adults has been provisionally recommended by the National Institute for Health and Care Excellence (NICE). In draft guidance, published on 18 November 2021 (https://www.nice.org.uk/guidance/indevelopment/gid-ta10658) , cabotegravir (Vocabria; ViiV Healthcare) with rilpivirine (Rekambys; Janssen) is recommended by NICE, within its marketing authorisation, as an option for adults with HIV-1, the most common type of HIV infection.
展开▼
